When the O’Neill family learned their four-year-old daughter Eliza had Sanfilippo syndrome, a rare and fatal degenerative disease, they launched an all-hands-on-deck fundraising campaign to accelerate medical research. NPR pharmaceutical correspondent Sydney Lupkin discussed the family’s approach on the Short Wave podcast, highlighting the promises and hurdles of developing treatments for rare conditions.
What is Sanfilippo syndrome?
Sanfilippo syndrome is a rare, inherited condition that causes progressive degeneration in children. The fatal illness typically claims the lives of affected individuals by the time they reach their teens. When the O’Neill family received the diagnosis for their daughter Eliza, no treatments existed for the condition, according to NPR. Drug developers historically focused their resources on more common illnesses rather than rare pediatric diseases.
How did the family raise research money?
Faced with a terminal diagnosis and a lack of existing therapies, the family took an unusual approach to directly fund medical science. Glenn, Beckham, Cara, and Eliza O’Neill posed for a family photo in 2015 as part of their visibility and fundraising efforts. By bypassing traditional funding bottlenecks, the family aimed to fast-track laboratory research toward a viable gene therapy.
Questions cover Eliza O'Neill, Sanfilippo syndrome, interview source
Eliza O’Neill is the daughter of Glenn and Cara O’Neill who was diagnosed with Sanfilippo syndrome at age four, prompting her family to launch a grassroots fundraising campaign.
What is Sanfilippo syndrome?
Sanfilippo syndrome is a rare, inherited, and degenerative disease that is typically fatal by the time a patient reaches their teenage years.

Where can listeners find the original interview?
The interview with pharmaceutical correspondent Sydney Lupkin is available on the Short Wave podcast via Spotify and Apple Podcasts, as noted by NPR.
Keep reading